Valbiotis SA (ALVAL.PA)
EUR 1.36
(-1.59%)
EUR 1.36
(-1.59%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 6.87 Million EUR | -4.17% |
| 2022 | 7.17 Million EUR | -5.47% |
| 2021 | 7.59 Million EUR | 8.26% |
| 2020 | 7.01 Million EUR | 46.84% |
| 2019 | 4.77 Million EUR | 70.45% |
| 2018 | 2.8 Million EUR | 65.51% |
| 2017 | 1.69 Million EUR | 110.05% |
| 2016 | 806 Thousand EUR | 5.91% |
| 2015 | 761 Thousand EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q2 | 6.72 Million EUR | 0.0% |
| 2023 Q4 | 6.88 Million EUR | 0.0% |
| 2023 FY | 6.87 Million EUR | -4.17% |
| 2022 FY | 7.17 Million EUR | -5.47% |
| 2022 Q2 | 7.17 Million EUR | 0.0% |
| 2022 Q4 | 7.17 Million EUR | 0.0% |
| 2021 FY | 7.59 Million EUR | 8.26% |
| 2021 Q4 | 7.59 Million EUR | 0.0% |
| 2021 Q2 | 7.9 Million EUR | 0.0% |
| 2020 Q4 | 7.01 Million EUR | 0.0% |
| 2020 Q2 | 4.5 Million EUR | 0.0% |
| 2020 FY | 7.01 Million EUR | 46.84% |
| 2019 Q2 | 4.55 Million EUR | 0.0% |
| 2019 Q4 | 4.77 Million EUR | 0.0% |
| 2019 FY | 4.77 Million EUR | 70.45% |
| 2018 FY | 2.8 Million EUR | 65.51% |
| 2018 Q4 | 2.8 Million EUR | 0.0% |
| 2018 Q2 | 1.64 Million EUR | 0.0% |
| 2017 Q2 | 1.14 Million EUR | 0.0% |
| 2017 Q4 | 1.69 Million EUR | 0.0% |
| 2017 FY | 1.69 Million EUR | 110.05% |
| 2016 Q4 | 806 Thousand EUR | 0.0% |
| 2016 FY | 806 Thousand EUR | 5.91% |
| 2015 FY | 761 Thousand EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -102.891% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 87.599% |
| Adocia SA | 13.08 Million EUR | 47.448% |
| Aelis Farma SA | 4.03 Million EUR | -70.332% |
| Biophytis S.A. | 8.27 Million EUR | 16.832% |
| Advicenne S.A. | 17.42 Million EUR | 60.528% |
| genOway Société anonyme | 7.23 Million EUR | 4.913% |
| IntegraGen SA | 1.12 Million EUR | -511.522% |
| Medesis Pharma S.A. | 1.2 Million EUR | -473.167% |
| Neovacs S.A. | 650 Thousand EUR | -958.154% |
| NFL Biosciences SA | 62.17 Thousand EUR | -10962.502% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -57.879% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -153.162% |
| Sensorion SA | 2.86 Million EUR | -139.753% |
| Theranexus Société Anonyme | 3.64 Million EUR | -88.799% |
| TME Pharma N.V. | 1.16 Million EUR | -489.88% |
| TheraVet SA | 1.15 Million EUR | -492.999% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | 23.561% |
| argenx SE | 18.1 Million EUR | 62.011% |
| BioSenic S.A. | 28.16 Million EUR | 75.576% |
| Celyad Oncology SA | 902 Thousand EUR | -662.528% |
| DBV Technologies S.A. | 13.01 Million USD | 47.168% |
| Galapagos NV | 9.59 Million EUR | 28.324% |
| Genfit S.A. | 70.17 Million EUR | 90.199% |
| GeNeuro SA | 7.73 Million EUR | 11.112% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -29.921% |
| Innate Pharma S.A. | 39.89 Million EUR | 82.759% |
| Inventiva S.A. | 37.4 Million EUR | 81.613% |
| MaaT Pharma SA | 14.07 Million EUR | 51.133% |
| MedinCell S.A. | 58.96 Million EUR | 88.335% |
| Nanobiotix S.A. | 50.56 Million EUR | 86.398% |
| Onward Medical N.V. | 16.87 Million EUR | 59.239% |
| Oryzon Genomics S.A. | 13.68 Million EUR | 49.749% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 84.983% |
| Oxurion NV | 12.33 Million EUR | 44.235% |
| Pharming Group N.V. | 155.29 Million EUR | 95.571% |
| Poxel S.A. | 46.9 Million EUR | 85.335% |
| GenSight Biologics S.A. | 18.42 Million EUR | 62.676% |
| Transgene SA | 1.25 Million EUR | -447.176% |
| Financière de Tubize SA | 79.2 Million EUR | 91.316% |
| UCB SA | 3.03 Billion EUR | 99.774% |
| Valneva SE | 208.81 Million EUR | 96.706% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -18000.0% |